uvea

(redirected from uveal)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to uveal: Uveal tract, ocular adnexa

uvea

[′yü·vē·ə]
(anatomy)
The pigmented, vascular layer of the eye: the iris, ciliary body, and choroid.
References in periodicals archive ?
The registry will include institutions from across the US, UK and Australia, and is currently being developed by leaders in the field of uveal melanoma, including Richard Carvajal, MD, director of Experimental Therapeutics and director of the Melanoma Service at Columbia University Medical Center, Columbia University, US; Joseph Sacco, PhD, Clinical Senior Lecturer at the University of Liverpool and Honorary Consultant in Medical Oncology at Clatterbridge Cancer Centre, UK; and Anthony Joshua, MBBS, PhD, director of Cancer Services at St Vincent's Hospital and conjoint Associate Professor with the University of New South Wales, Australia
In-the-bag placement of the IOL is preferred because it mostly eliminates the risk of lens dislocation, iris capture, and uveal inflammation.
Merina Thomas, M.D., from the University of Michigan in Ann Arbor, and colleagues describe three patients who developed uveal effusion after initiation of anti-PD-1 and anti-PD-L1 monoclonal antibody therapy.
"The fear is, of course, patients who are BAPl mutation carriers might be predisposed to more lethal variants of uveal melanoma."
Inclusion criteria were the following: (i) stage III-C to IV (advanced) mucosal or uveal melanoma, whose diagnosis was histologically confirmed either on the primary tumor or on a metastasis; (ii) patients who received at least one infusion of anti-CTLA-4 or anti-PD-1 mAbs used either as first or second line, between 2008 and 2016; (iii) patients in the chemotherapy subgroup were treated with at least one cycle of chemotherapy, including carboplatin, fotemustine, dacarbazine, or temozolomide between 2000 and 2016 without further immunotherapy or BRAF or MEK inhibitors; (iv) minimal follow-up of 3 months after the first cycle of treatment in alive patients; and (v) radiologic assessment of tumor response at Week 12 with CT scan.
A nontumour cell line, hTERT-RPE1, and a uveal melanoma cell line, SOM-196b, previously shown to possess low SCE levels [13] were used as normal and low SCE controls, respectively.
Orbital exenteration for uveal melanomas with extrascleral spread is considered only in presence of gross orbital tumour extension [13].
Uveal melanoma (UM) is significantly less common than cutaneous melanoma and has a distinct molecular pathogenesis.
Most uveal melanomas could be treated with plaque radiation therapy or enucleation (removal of the eye that leaves the eye muscles and remaining orbital contents intact).
A defective immune system, specifically triggered and propelled by cytotoxic T cells against target organs including gastrointestinal tract (inflammatory bowel disease), synovial cartilage (rheumatoid arthritis), uveal membrane (anterior uveitis), myelin basic protein (multiple sclerosis), bone marrow (aplastic anemia) etc.
The uveal tract, which is the most vascular part of the eye, is the most likely to be affected.